Your browser doesn't support javascript.
loading
Diagnostic Tests to Support Late-Stage Control Programs for Schistosomiasis and Soil-Transmitted Helminthiases.
Hawkins, Kenneth R; Cantera, Jason L; Storey, Helen L; Leader, Brandon T; de Los Santos, Tala.
Afiliação
  • Hawkins KR; Diagnostics Program, PATH, Seattle, Washington, United States of America.
  • Cantera JL; Diagnostics Program, PATH, Seattle, Washington, United States of America.
  • Storey HL; Diagnostics Program, PATH, Seattle, Washington, United States of America.
  • Leader BT; Diagnostics Program, PATH, Seattle, Washington, United States of America.
  • de Los Santos T; Diagnostics Program, PATH, Seattle, Washington, United States of America.
PLoS Negl Trop Dis ; 10(12): e0004985, 2016 12.
Article em En | MEDLINE | ID: mdl-28005900
ABSTRACT
Global efforts to address schistosomiasis and soil-transmitted helminthiases (STH) include deworming programs for school-aged children that are made possible by large-scale drug donations. Decisions on these mass drug administration (MDA) programs currently rely on microscopic examination of clinical specimens to determine the presence of parasite eggs. However, microscopy-based methods are not sensitive to the low-intensity infections that characterize populations that have undergone MDA. Thus, there has been increasing recognition within the schistosomiasis and STH communities of the need for improved diagnostic tools to support late-stage control program decisions, such as when to stop or reduce MDA. Failure to adequately address the need for new diagnostics could jeopardize achievement of the 2020 London Declaration goals. In this report, we assess diagnostic needs and landscape potential solutions and determine appropriate strategies to improve diagnostic testing to support control and elimination programs. Based upon literature reviews and previous input from experts in the schistosomiasis and STH communities, we prioritized two diagnostic use cases for further exploration to inform MDA-stopping decisions and post-MDA surveillance. To this end, PATH has refined target product profiles (TPPs) for schistosomiasis and STH diagnostics that are applicable to these use cases. We evaluated the limitations of current diagnostic methods with regards to these use cases and identified candidate biomarkers and diagnostics with potential application as new tools. Based on this analysis, there is a need to develop antigen-detecting rapid diagnostic tests (RDTs) with simplified, field-deployable sample preparation for schistosomiasis. Additionally, there is a need for diagnostic tests that are more sensitive than the current methods for STH, which may include either a field-deployable molecular test or a simple, low-cost, rapid antigen-detecting test.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esquistossomose / Solo / Pessoal de Laboratório Médico / Testes Diagnósticos de Rotina / Helmintíase Tipo de estudo: Diagnostic_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Child / Female / Humans / Male País/Região como assunto: Europa Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esquistossomose / Solo / Pessoal de Laboratório Médico / Testes Diagnósticos de Rotina / Helmintíase Tipo de estudo: Diagnostic_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Child / Female / Humans / Male País/Região como assunto: Europa Idioma: En Ano de publicação: 2016 Tipo de documento: Article